Results 61 to 70 of about 43,043 (156)

Biopharmaceuticals for Cancer Treatment: An Update [PDF]

Cancer Med
ABSTRACT Cancer is one of the most debilitating diseases, causing profound physical and psychological impacts on patients. The global number of cancer patients has been steadily rising over the last few decades. The development of effective cancer therapies remains the primary focus in life science research, requiring a precise understanding of ...
Nath A, Alam Y, Mim A, Akter M, Gani M, Alam K, Alam M.   +6 more
europepmc   +2 more sources

Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia [PDF]

, 2016
Deregulated expression of the type I cytokine receptor, CRLF2, is observed in 5–15% of precursor B-cell acute lymphoblastic leukaemia (B-ALL). We aimed to determine the clinical and genetic landscape of those with IGH-CRLF2 or P2RY8-CRLF2 (CRLF2-r) using
Campbell, PJ, Enshaei, A, Eswaran, J, Fielding, AK, Harrison, CJ, Jones, L, Moorman, AV, Nakjang, S, Papaemmanuil, E, Russell, LJ, Ryan, SL, Tonin, S, Tubio, JMC, Vora, A   +13 more
core   +1 more source

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia [PDF]

, 2016
Increasing knowledge concerning the biology of hematologic malignancies as well as the role of the immune system in the control of these diseases has led to the development and approval of immunotherapies that are resulting in impressive clinical ...
Abonour, Rafat, Anderson, Kenneth C., Ansell, Stephen M., Avigan, David, Barbarotta, Lisa, Barrett, Austin John, Bergsagel, Leif, Bishop, Michael R., Borrello, Ivan, Boyiadzis, Michael, Brody, Joshua, Brufsky, Jill, Cairo, Mitchell, Chari, Ajai, Cohen, Adam, Cortes, Jorge, de Lima, Marcos, Dhodapkar, Madhav V., Forman, Stephen J., Friedberg, Jonathan W., Fuchs, Ephraim J., Gore, Steven D., Jagannath, Sundar, Kahl, Brad S, Kline, Justin, Kochenderfer, James N., Kwak, Larry W., Levy, Ronald, Litzow, Mark R., Mahindra, Anuj, Miller, Jeffrey, Munshi, Nikhil C., Orlowski, Robert Z., Pagel, John M., Porter, David L., Russell, Stephen J., Schwartz, Karl, Shipp, Margaret A., Siegel, David, Stone, Richard M., Tallman, Martin S., Timmerman, John M., Van Besien, Koen, Van Rhee, Frits, Waller, Edmund K., Welsh, Ann, Werner, Michael, Wiernik, Peter H.   +47 more
core   +5 more sources

T-Lymphoblastic Lymphoma with an Unusual t(8;14)(q24;q11) – Case Report [PDF]

, 2010
Cytogenetic abnormalities seen at presentation of acute lymphoblastic leukemia or lymphoblastic lymphoma (ALL/ LBL) are associated with distinct clinical and hematologic disease entities.
Ika Kardum-Skelin, Inga Mandac, Jasminka Jakelić-Piteša, Radovan Vrhovac, Ružica Lasan-Trčić, Slobodanka Ostojić Kolonić   +5 more
core   +1 more source

Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34+ progenitor cells during differentiation into antigen presenting cells [PDF]

, 2001
The inducible costimulator receptor (ICOS) is a third member of the CD28 receptor family that regulates T cell activation and function. ICOS binds to a newly identified ligand on antigen presenting cells different from the CD152 ligands CD80 and CD86. We
Aicher, A, Clark, EA, Daemen, K, Hayden-Ledbetter, M, Irgang, M, Korner, I, Ledbetter, JA, Pezzutto, A, Richter, G, Westermann, J   +9 more
core  

Mediastinal neoplasms in patients with Graves disease: a possible link between sustained hyperthyroidism and thymic neoplasia? [PDF]

, 2012
Background Anterior mediastinal masses are a rare but well documented finding in Graves disease. The vast majority of these lesions represents benign thymic hypertrophy and regress after treatment of the hyperthyroidism.
Boyd, Jonathan D, Juskevicius, Ridas
core   +2 more sources

Biological and clinical characteristics of ETV6::RUNX1‐like ALL

HemaSphere, Volume 10, Issue 4, April 2026.
Abstract ETV6::RUNX1‐like ALL is defined by a gene expression signature similar to that of ETV6::RUNX1‐positive ALL and absence of all genetic subtype‐defining aberrations, including the ETV6::RUNX1 fusion. Within the International BFM Study Group, we assembled and analyzed a cohort of 100 patients (including 97 children) with ETV6::RUNX1‐like ALL.
Marketa Zaliova, Dagmar Schinnerl, Judith M. Boer, Aurélie Caye‐Eude, Jacqueline Rehn, Claire Schwab, Chloé Arfeuille, Andishe Attarbaschi, Anke Katharina Bergmann, Karel Fiser, Hester A. de Groot‐Kruseman, Sabrina Haslinger, Andrea Inthal, Iveta Janotova, Lennart Lenk, Margarita Maurer‐Granofszky, Karin Nebral, Fiona Poyer, Lucie Sramkova, Jan Stary, Marion Strullu, Jan Stuchly, Rosemary Sutton, Martina Vaskova, Lucie Winkowska, Gunnar Cario, Hélène Cavé, Monique L. den Boer, Christine Harrison, Sabine Strehl, Deborah White, Jan Trka, Jan Zuna   +32 more
wiley   +1 more source

Novel strategy for rapid functional in vivo validation of oncogenic drivers in haematological malignancies [PDF]

, 2019
In cancer research, it remains challenging to functionally validate putative novel oncogenic drivers and to establish relevant preclinical models for evaluation of novel therapeutic strategies.
Berx, Geert, D'Hont, Jinke, Demoen, Lisa, Goossens, Steven, Haenebalcke, Lieven, Haigh, Jody J., Hochepied, Tino, Lammens, Tim, Lemeire, Kelly, Lintermans, Béatrice, Matthijssens, Filip, Pedro Pinto De Almeida, André, Pieters, Tim, Reunes, Lindy, T'Sas, Sara, Van Vlierberghe, Pieter, Vanrockeghem, Frédérique   +16 more
core   +3 more sources

Prethymic Cytoplasmic CD3 Negative Acute Lymphoblastic Leukemia or Acute Undifferentiated Leukemia: A Case Report [PDF]

, 2013
Acute undiffentiated leukemia (AUL) is an acute leukemia with no more than one membrane marker of any given lineage. Blasts often express HLA-DR, CD34, and/or CD38 and may be positive for terminal deoxynucleotidyl transferase (TdT).
Azzarà, Antonio, Cannizzo, Elisa, Carulli, Giovanni, Del Vecchio, Luigi, Galimberti, Sara, Ottaviano, Virginia, Petrini, Mario, Preffer, Frederic Ira   +7 more
core   +1 more source

Nanobody based dual specific CARs [PDF]

, 2018
Recent clinical trials have shown that adoptive chimeric antigen receptor (CAR) T cell therapy is a very potent and possibly curative option in the treatment of B cell leukemias and lymphomas.
Abken, Hinrich, Bonte, Sarah, De Munter, Stijn, Goetgeluk, Glenn, Ingels, Joline, Kerre, Tessa, Pille, Melissa, Vandekerckhove, Bart, Weening, Karin   +8 more
core   +2 more sources